Recombinant Zoster Vaccine Demonstrates High Protection Against Shingles in Adult Patients
The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.
Comunidad Autonoma De Cataluna Phil Dormitzer Biomedical Research Of The Valencian Community Foundation For The Promotion Of Health European Society Of Clinical Microbiology Long Term Follow Up Study
Source: pharmacytimes.com